370 results
Search Results
2. Letter: Exploring the clinical utility of ammonia in critically ill patients with cirrhosis: More to do? Authors' reply.
3. Letter: Exploring the clinical utility of ammonia in critically ill patients with cirrhosis: More to do?
4. Meta-analysis: mortality in Crohn’s disease.
5. Editorial: terlipressin in patients with ACLF grade 3—too late? Authorsʼ reply.
6. Letter: PCSK9 inhibitor for liver transplant patients during the post‐statin era? Authors' reply.
7. Editorial: Non‐selective beta‐blockers: A lifesaving shield for critically ill patients with acute decompensation of cirrhosis?
8. Editorial: risk of loss of response to anti TNFα in patients with inflammatory bowel diseases – the longer the less? Authors' reply.
9. Editorial: early TIPSS in patients with cirrhosis and acute variceal bleeding—the plot thickens!
10. Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti‐TNF‐therapy—authors' reply.
11. Letter: immunogenicity is not the root cause for loss of response to anti‐TNF agents in patients with IBD in TDM era.
12. Letter: Addressing opioid exposure and associated harms in patients with IBD.
13. Editorial: in the era of effective antiviral therapy, long‐term dynamic endoscopic monitoring does not seem to be necessary for all CHB patients with compensated cirrhosis.
14. Editorial: bezafibrate in the treatment of patients with primary biliary cholangitis—are we there yet? Authors' reply.
15. Letter: screening for infectious side effects in patients with IBD—the importance and potential of real‐world remote monitoring.
16. Editorial: risk of loss of response to anti‐TNFα agents in patients with inflammatory bowel disease—the longer the less?
17. Letter: should we abandon FIB‐4 to characterise noninvasively patients with NAFLD? Authors' reply.
18. Letter: should we abandon FIB‐4 to characterise non‐invasively patients with NAFLD?
19. Editorial: definition of factors associated with poor quality of life in patients with IBS—but where to from here? Authorsʼ reply.
20. Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find. Author's reply.
21. Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find.
22. Editorial: Novel insights into the prognostic relevance of high‐dose PPI treatment in patients with cirrhosis.
23. Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed. Authors' reply.
24. Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed.
25. Letter: opioid usage is associated with rectal hyposensitivity in patients with opioid‐induced constipation.
26. Editorial: symptoms predicting active intestinal inflammation in patients with IBD.
27. Editorial: terlipressin in patients with acute‐on‐chronic liver failure grade 3—too late?
28. Letter: the duration of a patient's long‐term stability on anti‐TNFs should be considered before nonmedical switching to a biosimilar.
29. Letter: TIPSS improves muscle mass indices in patients with cirrhosis and severe portal hypertension – authors' reply.
30. Editorial: rectal hyposensitivity in patients with hypermobile Ehlers‐Danlos syndrome and constipation—authors' reply.
31. Editorial: progress towards more comprehensively understanding the sources of corticosteroids for patients with IBD.
32. Editorial: Percutaneous placement of a permanent tunnelled catheter for patients with non‐malignant ascites—Is it safe?
33. Letter: screening for infectious side effects in patients with IBD—the importance and potential of real‐world remote monitoring. Authors' reply.
34. Meta-analysis: the use of non-steroidal anti-inflammatory drugs and pancreatic cancer risk for different exposure categories.
35. Letter: immunotherapy in IBD patients in a SARS‐CoV‐2 endemic area.
36. Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era—getting nearer? Authors' reply.
37. Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era—getting nearer?
38. Editorial: 5‐ASA in IBD patients on biologics—'stop or continue'? Authors' reply.
39. Editorial: hepatitis C virus (HCV) disease progression - HCV cure and the elimination of the 'ethnic slope'.
40. Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti‐TNF therapy.
41. Letter: predictors of survival in patients undergoing transjugular intrahepatic portosystemic shunt—what should we assess by ultrasound?
42. Editorial: bezafibrate in the treatment of patients with primary biliary cholangitis—are we there yet?
43. Editorial: percutaneous placement of a permanent tunnelled catheter for patients with non‐malignant ascites ‐ is it safe? Authors' reply.
44. Letter: patients who have both sarcopenia and frailty have similar prognosis to those with either condition separately—authors' reply.
45. Letter: patients who have both sarcopenia and frailty have similar prognosis to those with either condition separately.
46. Editorial: 5‐ASA in IBD patients on biologics—'stop or continue'?
47. Letter: extending FIT from DG30 to NG12 patients.
48. Letter: liver involvement and mortality in COVID‐19 patients.
49. Letter: diarrhoea in obese patients—a new nosographic entity?
50. Editorial: topiramate for cyclic vomiting syndrome—for refractory patients only?
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.